Oncolytics Biotech Inc. Welcomes Andrew Aromando as New Chief Business Officer

Oncolytics Biotech Inc. Appoints Andrew Aromando as Chief Business Officer

Oncolytics Biotech Inc. announces the strategic appointment of Andrew Aromando as its new Chief Business Officer, effective June 30, 2025. With over three decades of experience in the life sciences sector, Aromando's robust background positions him to significantly impact Oncolytics' business development initiatives. His tenure as Chief Operating Officer at Ambrx Biopharma is particularly noteworthy, as he played an integral role in the company’s $2 billion acquisition by Johnson & Johnson, showcasing his expertise in navigating complex corporate transactions and strategic partnerships.

In his new role at Oncolytics, Aromando will focus on overseeing global business development and shaping corporate, clinical, and regulatory strategies. A major emphasis will be placed on enhancing the value of Oncolytics' extensive clinical data for its lead product, pelareorep. This innovative therapy is currently being evaluated for its efficacy against various tumor types, including pancreatic, breast, and anal cancers. Aromando's extensive experience in C-level positions across oncology-focused biopharma companies equips him with the insights necessary to optimize product commercialization and portfolio strategies, ensuring that Oncolytics can effectively leverage its clinical advancements in a competitive market.

Aromando’s academic credentials, which include a Bachelor’s degree from The College of New Jersey and a Master’s degree from Rutgers University, further underpin his suitability for the role. His appointment aligns seamlessly with Oncolytics' mission to advance its clinical programs and maximize the potential of its therapies in the oncology landscape. The company is poised for growth under his leadership, as Aromando's strategic vision will be pivotal in navigating the evolving challenges of the biopharmaceutical industry.

In other developments, Oncolytics remains committed to enhancing its clinical research initiatives and expanding its pipeline of innovative cancer therapies. The strategic leadership provided by Aromando is expected to facilitate collaborations and partnerships that could accelerate the development and commercialization of pelareorep and other promising therapies. As the company continues to position itself at the forefront of oncology innovation, Aromando's insights and experience will be invaluable in achieving its long-term goals.